The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial-Reference-Cited by-同舟云学术

The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial

Published:2022-05-31 Issue:8 Volume:57 Page:1319-1326
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Matthaiou Efthymia Iliana,Sharifi Husham,O’Donnell Christian^ORCID,Chiu Wayland^ORCID,Owyang Clark^ORCID,Chatterjee Paulami,Turk Ihsan,Johnston Laura,Brondstetter Theresa,Morris Karen,Cheng Guang-Shing^ORCID,Hsu Joe L.^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01716-4.pdf

Reference35 articles.

1. Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129:448–55. https://doi.org/10.1182/blood-2016-08-693507

2. Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48:819–24. https://doi.org/10.1038/bmt.2012.241

3. Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13:1932–9. https://doi.org/10.1513/AnnalsATS.201604-262OC

4. Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191:1242–9. https://doi.org/10.1164/rccm.201410-1818OC

5. King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92. https://doi.org/10.1056/NEJMoa1402582

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study);The Journal of Heart and Lung Transplantation;2024-09

2. Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation;Nature Medicine;2024-05-23

3. A Phase 2 Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation;2024

4. Pulmonary microbiome and transcriptome signatures reveal distinct pathobiologic states associated with mortality in two cohorts of pediatric stem cell transplant patients;2023-11-30

5. Worldwide Bronchiolitis obliterans research: A bibliometric analysis of the published literature between 2002 and 2022;Medicine;2023-07-14